Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.4, 2001-04, pp. : 653-666

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivastigmine: A Pharmacoeconomic Review of its Use in Alzheimers Disease

By Lamb H.M. Goa K.L.

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 303-318

Adis International

Access to resources Recommend Favorite

Rivastigmine: A Review of its Use in Alzheimer's Disease

By Spencer C.M. Noble S.

Drugs & Aging, Vol. 13, Iss. 5, 1998-11 ,pp. : 391-411

Adis International

Access to resources Recommend Favorite

Metrifonate: A Review of its Use in Alzheimers Disease

By Ormrod D. Spencer C.

CNS Drugs, Vol. 13, Iss. 6, 2000-06 ,pp. : 443-467

Adis International

Access to resources Recommend Favorite

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

By Gottwald M.D. Rozanski R.I.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1673-1682

Informa Healthcare

Access to resources Recommend Favorite

Alzheimer’s disease and related dementias:

By Williams M. Davis R.E.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 6, 1997-06 ,pp. : 735-759

Informa Healthcare

Access to resources Recommend Favorite